Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral PTH (1-34) in Healthy Subjects
NCT02202603Phase 1Completed
- Sponsor
- Entera Bio Ltd.
- Start
- Jul 2011
- Primary completion
- Aug 2013
- Countries
- 1
01
Overview
Phase 1, double-blind trial of teriparatide in hypoparathyroidism and osteoporosis (5 arms), sponsored by Entera Bio Ltd. Primary endpoint: Adverse events at 17 weeks. Started Jul 2011; status: completed.
02
Drugs
teriparatide
03
Conditions
hypoparathyroidismosteoporosis
Beyond the preview
Go deeper on NCT02202603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202603.